Halt of Celebrex Study Threatens Drug's Future, Other Trials
- 24 December 2004
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 306 (5705) , 2170
- https://doi.org/10.1126/science.306.5705.2170a
Abstract
New research indicates Pfizer9s COX-2 inhibitor Celebrex may cause increased risk of heart attacks and strokes, leading to the halting of some clinical trials involving the drug. Dozens of other COX-2 inhibitor trials are undergoing careful review. The scenario is strikingly similar to what happened this fall to Merck9s COX-2 inhibitor Vioxx, which the Food and Drug Administration subsequently removed from the market.Keywords
This publication has 0 references indexed in Scilit: